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Introduction. In conservative breast cancer surgery, removing all carcinogenic lesions is a sound basis for achieving 
therapeutic success. The cleanness of the cutting margin is usually assessed after surgery and any residual cancerous 
tissue that are found, require further surgery. A simple and cheap assessment method is presented which can be 
used during surgery, the dielectric cancer probe (DCP), which allows the surgeon to take fast decisions on whether 
to extend incisions. 
Method. The DCP method consists of measuring and then differentiating between the electrical properties (perme-
ability and conductivity) of healthy and cancerous breast tissue. A polyethylene strip is used to separate the examined 
tissue from the instrument probe and the procedure is carried out by the operating surgeon. 
Results. This method was found to allow correct identification of cancerous breast tissue based on taking 189 samples 
from 70 patients using the intraoperative hand probe. The sensitivity and specificity were respectively 87% and 99%. 
Conclusions. The DCP is a high sensitivity method and is totally safe for the patient and can be used intraoperatively. 
The device is an aid to the surgeon for differentiating between healthy and cancerous breast tissue. Its widespread 
use should reduce the number of reoperations in the conservative surgical management of breast cancer patients.
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Introduction
Breast cancer is the most common malignancy found in 
women aged 45–70 years in developed countries and is the 
most common cause of cancer related death [1].
There are several methods of treating breast cancer, 
however surgery remains the treatment of choice for cases 
of non-advanced disease. The aim of surgery is to secure 
clear resection margins. This can be achieved by mastec-
tomy or breast conserving treatment (BCT). The success of 
local treatment depends on having clear resection margins. 
Residual cancer in resection margins can be found in as 
many as 20–46% of patients treated by BCT [2–4] which 
significantly increases the risk of recurrence, with ductal car-
cinoma in situ (DCIS) being particularly difficult to excise [5]. 
It is therefore vital to evaluate the clearance of excision 
margins. Routine examinations are undertaken by the his-
topathologist on samples harvested from the surface of the 
excised tissue [6]. This can of course be carried out intra-
operatively, but since it is very time consuming it cannot 
be a standard approach. Such postoperative histopathology 
is accurate and has low false negativity, nevertheless its 
drawback is that hospital readmission and reoperation are 
required whenever cancerous tissue are found within the 
surgical involvement margins. There are also other methods 
of margin assessment available such as imprint cytology [7] 
and near IR fluorescence [8] or high frequency U/S [9].
The dielectric technique is a relatively new method [2, 
10, 11]. It measures electric permittivity and conductivity 
which are known to differ between normal and malignant 
tissue [12–14]. These parameters are lowest in fat tissue 
and are significantly lower than in cancerous tissue [15, 16] 
thus allowing differentiation between these tissue states. 
Laboratory testing has demonstrated such differences in 
clean and dried samples [17–19], however in real-life situa-
tions the presence of blood and serum interferes with such 
measurements by apparently increasing the permittivity 
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and conductivity in normal tissue to those levels found in 
malignant tissue. For this reason the method is problematic 
for use during surgery [21, 22].
This study demonstrates the use of a probe with so-
called blocked electrodes, where the electric sensor does 
not come into direct contact with the examined tissue but 
is separated by a thin layer of insulation (polyethylene film) 
[18–20] thus avoiding the conflicting interference from 
blood and serum. The insulating polyethylene between the 
probe and sample ensures sterility of the field of operation, 
thus allowing multiple uses of the same probe. This investi-
gation aims to assess the value and reliability of the dielectric 
method in differentiating between normal from malignant 
tissue as well as whether it can be used for assessing the 
cleanness of the cutting margin during breast surgery and 
detecting any new foci of cancer (DTABCS — Dielectric 
Technique Assisted Breast Cancer Surgery). In particular, 
the study tests a prototype hand held probe, developed, 
manufactured and patented in Poland; the Dielectric Cancer 
Probe (DCP).
Materials and methods
Breast tissue samples were acquired at the time of sur-
gery carried out on 70 patients at the Regional Specialist 
Hospital in Wroclaw from 01/01/2013 to 30/09/2015. We 
obtained 189 samples from 32 patients undergoing mas-
tectomy and 34 patients having BCT; of these 4 patients 
had only local excisions for benign lumps.
Testing consisted of 94 normal breast tissue samples and 
95 that were histopathologically confirmed as being malig-
nant. Patient characteristics are shown in Table I. Samples 
were examined both intra-operatively and post-operatively. 
The standard sample was a thin sliver of tissue, harvested 
by the surgeon in such a way that it contained both normal 
and malignant tissue.
Obtaining samples for DCP was stand-alone and had 
no effect on those taken for the routine histopathological 
testing. DCP samples were stored in sealed containers at 
5°C temperature and underwent dielectric testing within 
24 hours since their acquisition. We confirmed such a time 
delay had no effect whatsoever on outcome (Fig. 1). 
For the intra-operative tests, the tissue surface removed 
was checked for cleanliness and subsequently sent for his-
topathology. All measurements were carried out at room 
temperature (20–25°C). Consent of the bioethics commis-
sion prior to the launch of this study had been obtained.
Methods
Figure 2 shows the DCP hand held probe. It is a Maxwell 
Wagner layer capacitor. Instrumental readings were related 
to the electric parameters of the tissue examined (i.e. permit-
tivity and conductivity) and depend on the detector circuit 
and probe sensor geometry. The device is capable of obtain-
Table I. Patients’ characteristics
No of patients 70
Age
The youngest 25 y
The oldest 84 y
Average age 60.7 y
Preoperative diagnosis
Core biopsy 66
No biopsy 4
Histological type of tumour
Invasive ductal carcinoma 46
Invasive ductal carcinoma with DCIS component 10
Invasive lobular carcinoma 8
DCIS 1
Invasive metaplastic carcinoma 1
Fibroadenoma 4
Grading
G1 8
G2 38
G3 20
Angioinvasion 29
N1 29
Preoperative chemotherapy 5
Type of operation
Mastectomy 32
Breast conserving surgery 34
Lumpectomy 4
Number of investigated specimens
Tumour tissue 95
Healthy tissue 94
Figure 1. Dependence between sampling and measurement times. 
Curves are superimposed
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ing readings ranging from 1 to 120 units depending on the 
type of tissue; with adipose tissue giving the lowest and 
cancer the highest. An operating 100 MHz radio frequency 
was used which is harmless to patients. The probe has an 
oblong shape with a 25 mm2 sensor at its tip. Measurements 
are taken by pressing the probe against the tissue.
As aforementioned, a polyethylene sleeve was used to 
safeguard the sterility of the operations field and to elimi-
nate the interference of blood and serum exudate. There 
was no effect demonstrated of the potentially interfering 
conductible fluids on the instrument results as shown on 
Figures 3A and 3B; these showing the result of the test 
sample containing malignant tissue in the middle of the 
specimen. The Figure 3A high readings confirm malignancy 
of a blood-free sample whilst Figure 3B shows those of 
a sample dipped in normal saline. 
Technical data and construction details of the DCP are 
provided in its patent description [17]. The physics back-
Figure 2. Prototype of the hand-held dielectric probe
Figure 3. A dielectric map of measurements taken of a test sample containing malignant tissue in the middle of the specimen. High readings 
confirm malignancy of a blood-free sample (A) whilst a sample dipped in normal saline is shown in (B). No demonstrated effect of the conductible 
fluid on results
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ground of the measurements and the tests carried out on 
reference substances and animal tissue have been described 
in earlier publications from physics journals [18–20].
Laboratory testing has demonstrated that cancer tissue 
can be detected both on the surface of a specimen as well as 
underneath a 1–2 mm layer of healthy breast tissue [18, 19].
The DCP is a simple to use and inexpensive device. 
It takes 6–12 minutes to examine the whole specimen. Re-
sults are displayed on a screen and the detection of ma-
lignant tissue triggers an audible alarm. The DCP is only 
a prototype and it is not yet commercially available. All our 
study tests were performed on prototypes manufactured by 
Mr Stanisław Baj (Zakład Nowych Technologii, Owczarska St. 
42, 54–020 Wrocław, Poland; www.znt.com.pl).
Results
Figure 4 shows a cross sectional image of sample tissue 
(A) and a dielectric map (B) acquired by using the DCP dur-
ing the test of its ability to detect neoplastic changes. The 
image shows a pinkish area corresponding to cancer. The 
dielectric map (B) shows brown and red areas of high per-
mittivity and conductivity consistent with cancer, whereas 
the yellow and blue depict normal breast tissue. The close 
similarity between the images and dielectric maps are ex-
Figure 4. A — cross sectional image of a tissue sample containing 
neoplastic changes surrounded by healthy breast tissue, B — dielectric 
map
plicitly visible. This study as well as earlier publications [19, 
20] demonstrate multiple tests that have confirmed a cor-
rect differentiation between healthy and neoplastic tissue.
Statistical analysis showed for 100 MHz frequency, that 
the dielectric probe correctly distinguishes healthy breast 
tissue from malignancy. Instrument readings varied from 2 
to 36 units (mean 12) for normal breast tissue and 11 to 114 
units (mean 58) for cancer. A non- parametric Kruskal Wallis 
test was used for the statistical analysis. For both sample 
groups (i.e. normal and malignant) the number of samples 
(N), mean value (X), median (M), standard deviation (SD), 
range (min – max), lower and upper quartyl (25Q–75Q) 
were calculated. A highly significant value (p = 0.0000) was 
obtained by the Kruskal-Wallis test; results being shown in 
Table II. The correlation between pathology and the results 
of dielectric testing was analysed to assess the sensitivity 
and specificity of the tested method based on 189 samples, 
of which 94 had benign histopathology whilst 95 were ma-
lignant. Figure 5 shows the ROC curve (Receiver Operating 
Characteristics).
The shape of the ROC curve demonstrates a high diag-
nostic potential for the tested method. The Youden Index (YI) 
Figure 5. ROC curve. Correlation between sensitivity and specificity 
of the hand held DCP probe for detecting breast cancer
Table II. Results of the Kruskal-Wallis test
X N SD MIN MAX 25Q M 75Q
Healthy tissue 11.6 94 7.8 2.0 36.0 5.0 9.2 17.1
Tumour 58.8 95 21.6 11.3 114.1 41.5 65.2 77.1
112
was used to find the best cut off point which was calculated 
based on the sensitivity and specificity (YI = sensitivity + 
specificity –1). The maximum of YI, i.e. the optimum cut off 
point was achieved for a reading of 30 units. This value is 
more than twice as high as the mean value for normal tis-
sue. For the set cut off parameter, sensitivity and specificity 
were respectively 0.87 and 0.99. These results place DCP 
among one of the best intra-operative techniques that are 
used to assess the clearance of margins. Our probe is capa-
ble of correctly diagnosing normal and neoplastic tissue, 
however it is unable to differentiate between benign and 
malignant neoplasms. Because of the physical parameters 
of such tissue, it is however unlikely that we will be able to 
ever achieve this goal.
Analysing false negatives and false positives results is 
necessary for evaluating any new diagnostic tool/method. 
We found only one false positive, where a sample found 
to be benign on histopathology was reported as being 
malignant by the probe. This was a NST G2, LV+ve, LN+ve 
cancer. We also noted 10 false negatives, among them 8 NST 
cancers and 2 lobular ones. Eight tumours were G2 and two 
G3 stage. Six cases were LV+ve. Seven patients were treated 
with BCT and two received mastectomy. There was no cor-
relation between false positives/negatives and pathological 
features such as grade, LV and tumour type. We suspect that 
an inadequate contact between the probe and the sample or 
perhaps a too thick layer of fatty tissue (greater than 3 mm) 
could have been responsible.
Discussion
A significant number of patients who undergo BCT 
subsequently require additional surgery for the clearance 
of margins. In Poland there are approx. 18,000 new cases 
of breast cancer annually. If 50% of women undergo con-
servative treatment and 25 % of these require further sur-
gery, then we can assume that approx. 2,250 operations 
are performed annually to clear surgical margins after in-
complete excision. The odds are even higher for impalpable 
and multifocal lesions and for DCIS. It is however difficult 
to unequivocally establish the involvement of cancerous 
margins by histopathology, where this is confirmed in only 
63% cases of finding tumours in re-excision specimens [24]. 
Other studies have shown that cancer can still be found in 
margins wider than 2 mm. This can be explained by a lack of 
continuity of cancer infiltration or by technical and specimen 
handling issues (Fig. 6) [25].
Intra-operative and postoperative histopathology can 
make mistakes. The intra-operative device in the hands 
of experienced surgeon can significantly reduce the need 
for repeating surgery by giving the surgeon the chance to 
excise wider margins at the initial operation. The probe of 
course cannot be a substitute for a rigorous histopatho-
Figure 6. Pictures showing excised breast lump tissue (A) and an additional margin fragment (B). The difficulty posed to the pathologist is the lack 
of continuity of cancer infiltration and specimen fragmentation
A B
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logical examination. In the literature there some reports of 
instruments using similar techniques to DCP. Dune Medical 
Devices, Caesarea, Israel, offers the MarginProbe®. We would 
thereby like to include a review of their experience in order 
to compare their device with our DCP. In 2007, a study by 
T. Karni et al. intra-operatively assessed surgical margins 
using the MarginProbe® [26]. The sensitivity in detecting 
involved margins was 71% and the specificity was 68%, 
depending on the width of the margin.
Pappo et al. [30] conducted a similar study on 753 sam-
ples obtained from 76 patients. Sensitivity and specificity 
reached 70%, with the sensitivity increasing with the tu-
mour size and reaching 97% in lesions greater than 6 mm 
irrespective of the tumour type; our results having similar 
outcomes. A randomised trial by Thill et al was performed in 
2011 and 2014 using the MarginProbe® on patients treated 
with BCT for DCIS which demonstrated reduced re-excision 
rates by 17%. In 21% cases, mastectomy was performed as 
a one stage procedure thanks to this device [10, 11]. In 2012, 
Riwera et al following recommendations of the FDA, con-
ducted a multi-centre randomised trial which recruited 596 
women with impalpable tumours. The use of MarginProbe® 
reduced the need for a second operation from 29.9% to 
14.1%. A similar trial by Schnabel et al [2] yielded excision 
rates of 62% for positive margins vs 22% without the probe. 
In summary, the total number of re-operations was reduced 
by 6%. In 2015, Sebastian et al performed a retrospective 
analysis of the data collected from three centres on 165 
women subjects, where a 62% reduction in re-operations 
was achieved in those where the probe had been used [4]. 
According to all these studies, false positives and nega-
tives were linked to small sample size and to the presence 
of blood and serum with high conductivity. Our DCP is 
however not sensitive to such circumstances. 
As for now, the MarginProbe® has not been recommend-
ed by international authorities for treating breast cancer 
as a standard treatment in BCT [28, 29]. This reserved and 
cautious judgment is due to insufficient data on the impact 
of this device on local recurrence. The recommendation may 
yet still be granted should more supporting data appear. 
Just as in the case of the MarginProbe®, our study did 
not also find any correlation between the probe reading 
and the tumour type. What is more important, there are no 
such differences in DCIS which is diagnosed successfully as 
invasive cancer. The MarginProbe® has been so far intro-
duced mainly in Israel and the USA. There are some scanty 
reports also coming from Germany. The price of the console 
is 24,995 $ and the disposable probe costs 995 $. These costs 
are significantly higher than the predicted price of the com-
mercially available Polish DCP. Our probe is a multiple-use 
device which is capable of taking measurements in the 
presence of blood and serum within the field of operation. 
Conclusions
This study has presented test results of the Dielectric 
Cancer Probe (DCP) developed and manufactured in Poland. 
This instrument is designed for intra-operatively differenti-
ating between normal breast tissue from malignancy, and 
particularly for examining the clearance of surgical margins, 
as well as to search for residual cancer in the remaining post 
excision breast tissue. The background physics and how the 
method is used are similar to the commercially available 
MarginProbe® device. The advantage of our instrument over 
the latter is its insensitivity to the presence of blood and se-
rum within the field of operation. The DCP is also a multiple 
use and inexpensive device which has no disposable parts 
requiring replacement after each test procedure. It is safe to 
use intra-operatively with a sterile polyethylene sleeve. The 
DCP is relatively inexpensive. Our study has demonstrated its 
efficiency in detecting involved surgical margins. The probe 
is however unable to distinguish benign from malignant tu-
mours. The DCP accurately distinguishes and localises tissue 
that differs from normal breast parenchyma, not only on the 
surface of the specimen but also at a depth of 1–2 mm. The 
DCP should therefore be treated as a surgeon’s additional 
eye in helping to intra-operatively locate histopathologically 
abnormal tissue and thus aiding in taking the decision on 
whether any additional resection is required.
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